Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies

医学 肝细胞癌 内科学 CDKN2A 肿瘤科 列线图 胃肠病学 外科肿瘤学 癌症
作者
Yizhen Fu,Zhenyun Yang,Zili Hu,Zhoutian Yang,Yangxun Pan,Jinbin Chen,Juncheng Wang,Dandan Hu,Zhongguo Zhou,Li Xu,Minshan Chen,Yaojun Zhang
出处
期刊:Hepatology International [Springer Science+Business Media]
卷期号:16 (4): 868-878 被引量:35
标识
DOI:10.1007/s12072-022-10348-1
摘要

BackgroundCirculating tumor DNA (ctDNA) can be useful in tumor diagnosis and surveillance. However, its value in hepatocellular carcinoma (HCC) patients receiving curative resection remains unknown. Here, we aim to determine the prognostic value of ctDNA in HCC patients.MethodsA prospective cohort enrolled 258 HCC patients who underwent curative liver resection from April 1, 2019, to September 31, 2020. Blood samples were collected before surgery for the detection of ctDNA.ResultsThe number of total mutant genes in ctDNA was associated with early tumor relapse (HR = 2.2, p < 0.001). We defined a gene set consisting of APC, ARID1A, CDKN2A, FAT1, LRP1B, MAP3K1, PREX2, TERT and TP53 as high-risk genes (HRGs) associated with early recurrence. Patients were classified into low-, median- and high-risk levels based on the number of mutant genes in the HRGs. High-risk patients had worse recurrence free survival, especially single-tumor patients (HR = 13.0, p < 0.001). The risk level and TNM stage were independently associated with tumor recurrence. A preoperative recurrence estimation nomogram based on those two factors was constructed and demonstrated good accuracy with a C index of 0.76 (95% CI 0.70–0.82). Patients preserved FAT1 or LRP1B variants but without TP53 variants had worse progression free survival for receiving lenvatinib combined with immune checkpoint inhibitors after recurrence (HR = 17.1, p < 0.001). Furthermore, RNA sequencing data revealed that ctDNA status was associated with tumor immune infiltration.ConclusionPreoperative serum ctDNA can be a practical noninvasive approach to predict recurrence after surgery and response to systemic therapies. ctDNA-guided HCC management should be recommended.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
小叽发布了新的文献求助30
1秒前
ang完成签到,获得积分10
2秒前
2秒前
秋风的应助被AlphaAvery采纳,获得20
3秒前
xing_xing的应助被暖柚采纳,获得20
3秒前
慕青的应助被暖柚采纳,获得10
3秒前
李爱国的应助被美丽采纳,获得20
3秒前
FashionBoy的应助被小生不才采纳,获得10
3秒前
LLLLLLLLL完成签到,获得积分10
4秒前
GIK尘完成签到,获得积分10
4秒前
YMH完成签到,获得积分10
4秒前
张远幸发布了新的文献求助10
5秒前
石瑶发布了新的文献求助10
5秒前
Mottri完成签到,获得积分10
6秒前
JH_发布了新的文献求助10
6秒前
BTfaith发布了新的文献求助10
6秒前
苏逸发布了新的文献求助10
7秒前
inn完成签到,获得积分10
7秒前
华仔的应助被Xin5599采纳,获得10
7秒前
上官若男的应助被YMH采纳,获得10
8秒前
只一只鱼完成签到,获得积分10
8秒前
Maestro_S的应助被misscloud采纳,获得20
8秒前
8秒前
2711完成签到,获得积分10
8秒前
9秒前
9秒前
苗条的向雪完成签到 ,获得积分10
9秒前
10秒前
molihuakai的应助被HY采纳,获得10
10秒前
10秒前
11秒前
氯化钠完成签到,获得积分10
11秒前
贾磊完成签到,获得积分10
11秒前
lzy完成签到,获得积分10
11秒前
CQ完成签到 ,获得积分10
11秒前
12秒前
上官若男的应助被zyy采纳,获得30
13秒前
liuliu_完成签到 ,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820